Technology area: Biotechnology & Pharmaceuticals
16 pending office actions • 9 art units • 14 examiners • 0 of 16 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Xygenyx Inc. manages a robust portfolio within the Biotechnology & Pharmaceuticals technology area, currently navigating 16 pending office actions. This significant volume of active prosecution is spread across 9 distinct art units, suggesting that the company's biological and pharmaceutical innovations span multiple specialized examination groups. The involvement of 14 distinct examiners indicates a high degree of fragmentation in the prosecution process, requiring the applicant to manage a wide variety of examiner preferences and styles.
ALAM, AYAAN A is the busiest examiner for the company, yet they hold only 2 pending office actions. This means the remaining 14 pending actions are distributed among the other distinct examiners. Such a wide distribution across 14 distinct examiners and 9 distinct art units implies that no single examiner or art unit dominates the company's current legal landscape. Practitioners must prepare for diverse examination hurdles, as the 16 pending office actions are subject to the scrutiny of many different patent office personnel.
This decentralized structure requires a highly individualized approach to each application to account for the varied standards across the 9 distinct art units. The applicant cannot rely on a single strategy but must instead tailor their arguments to the specific technical and procedural expectations of the various individuals. Managing the Biotechnology & Pharmaceuticals portfolio in this environment demands significant coordination to ensure consistency. The 2 pending office actions held by the busiest examiner represent only a small fraction of the total active workload.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (19%) |
| §103 only | 8 (50%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 3 (19%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAM, AYAAN A | 2 | 38.8% | +36.4% |
| BRADLEY, CHRISTINA | 2 | 62.6% | +33.3% |
| TRAN, ERIC | 1 | 69.8% | +19.4% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
| TIEN, LUCY MINYU | 1 | 59.1% | +36.8% |
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
| LAZARO, DOMINIC | 1 | 63.7% | +31.2% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18299620 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | VARADARAJ, ARCHANA | 26d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18116849 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | BRADLEY, CHRISTINA | 296d overdue |
| 18299480 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | BUNNER, BRIDGET E | 21d |
| 18299453 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | BENAVIDES, JENNIFER ANN | 26d |
| 18295181 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | PARK, HAEJIN S | 34d |
| 18329491 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | RAO, PADMAJA S | 40d |
| 18329539 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | DEKARSKE, MADELINE MCGUIRE | — |
| 18118120 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | BRADLEY, CHRISTINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18116849 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | BRADLEY, CHRISTINA | 296d overdue |
| 18297841 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | ALAM, AYAAN A | 14d |
| 18299480 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | BUNNER, BRIDGET E | 21d |
| 18299620 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | VARADARAJ, ARCHANA | 26d |
| 18329491 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | RAO, PADMAJA S | 40d |
| 18329496 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | TIEN, LUCY MINYU | 70d |
| 18299716 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | LAZARO, DOMINIC | 84d |
| 18338310 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | TRAN, ERIC | — |
| Art Unit | Apps |
|---|---|
| 1611 | 4 |
| 1629 | 2 |
| 1675 | 2 |
| 1614 | 2 |
| 1654 | 2 |
| 1612 | 1 |
| 1627 | 1 |
| 1658 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18338310 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | TRAN, ERIC | 1629 | §103 | Final Rejection | — | Pending | Jun 20, 2023 |
| 18338304 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | NEAGU, IRINA | 1629 | §103 | Final Rejection | — | Pending | Jun 20, 2023 |
| 18329539 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | DEKARSKE, MADELINE MCGUIRE | 1675 | §103§112DP | Non-Final OA | — | Pending | Jun 05, 2023 |
| 18329496 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | TIEN, LUCY MINYU | 1612 | §103 | Non-Final OA | 70d | Pending | Jun 05, 2023 |
| 18329491 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | RAO, PADMAJA S | 1627 | §101§103 | Final Rejection | 40d | Pending | Jun 05, 2023 |
| 18299716 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | LAZARO, DOMINIC | 1611 | §103 | Final Rejection | 84d | Pending | Apr 13, 2023 |
| 18299620 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | VARADARAJ, ARCHANA | 1658 | §103 | Non-Final OA | 26d | Pending | Apr 12, 2023 |
| 18299480 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | BUNNER, BRIDGET E | 1647 | §103§112 | Final Rejection | 21d | Pending | Apr 12, 2023 |
| 18299484 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | ALAM, AYAAN A | 1611 | §103 | Final Rejection | — | Pending | Apr 12, 2023 |
| 18299453 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112 | Final Rejection | 26d | Pending | Apr 12, 2023 |
| 18297841 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | ALAM, AYAAN A | 1611 | §112 | Non-Final OA | 14d | Pending | Apr 10, 2023 |
| 18297535 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | 70d | Pending | Apr 07, 2023 |
| 18295188 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | GHALI, ISIS A D | 1611 | §103 | Non-Final OA | — | Pending | Apr 03, 2023 |
| 18295181 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | PARK, HAEJIN S | 1614 | §103§112 | Non-Final OA | 34d | Pending | Apr 03, 2023 |
| 18118120 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | BRADLEY, CHRISTINA | 1654 | §101§103 | Final Rejection | — | Pending | Mar 06, 2023 |
| 18116849 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | BRADLEY, CHRISTINA | 1654 | §101§103§112 | Non-Final OA | 296d overdue | Pending | Mar 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXygenyx Inc. has 16 pending office actions as of October 2026, spread across 9 art units and 14 examiners.
Ayaan A Alam has the most, with 2 of Xygenyx Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
